• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

20(S)-喜树碱内酯和羧酸盐形式在麻醉大鼠体内的血浆药代动力学

Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats.

作者信息

Scott D O, Bindra D S, Stella V J

机构信息

Department of Pharmaceutical Chemistry, University of Kansas, Lawrence 66044.

出版信息

Pharm Res. 1993 Oct;10(10):1451-7. doi: 10.1023/a:1018919224450.

DOI:10.1023/a:1018919224450
PMID:8272406
Abstract

20(S)-Camptothecin exists in equilibrium between its lactone (CPT) and its carboxylate forms (Na-CPT) under stimulated physiological conditions, with the equilibrium favoring the carboxylate form. The rates of lactone hydrolysis were studied in plasma, serum albumin, and blood and were found to be faster than in aqueous buffers at equivalent pH values. From mechanistic information and in vivo activity data, the lactone appears to be the active form of the drug. It has been argued, therefore, that if an equilibrium existed between the lactone and the carboxylate, Na-CPT could be used to deliver the lactone effectively. In the present study, plasma pharmacokinetics were performed in sodium pentobarbital-anesthetized rats treated with both CPT (lactone) and the sodium salt of camptothecin (carboxylate, Na-CPT) and the lactone and carboxylate, as well as the total drug, concentration versus time profiles were assessed. It was found that plasma concentrations and AUC values for the lactone were significantly higher after dosing with CPT than after dosing with Na-CPT. After i.v. administration, the ratio of plasma lactone to carboxylate was skewed by the apparent rapid and extensive uptake of the lactone into tissues and the rapid clearance of both species. From our results, it appears that the lower in vivo activity of Na-CPT compared to that from CPT administration might be attributed to the altered conversion of carboxylate into lactone in vivo compared to that predicted from in vitro data.

摘要

在刺激的生理条件下,20(S)-喜树碱在其内酯形式(CPT)和羧酸盐形式(Na-CPT)之间存在平衡,且该平衡有利于羧酸盐形式。研究了内酯在血浆、血清白蛋白和血液中的水解速率,发现其水解速率比在相同pH值的水性缓冲液中更快。从机理信息和体内活性数据来看,内酯似乎是药物的活性形式。因此,有人认为,如果内酯和羧酸盐之间存在平衡,Na-CPT可有效地递送内酯。在本研究中,对用CPT(内酯)和喜树碱钠盐(羧酸盐,Na-CPT)处理的戊巴比妥钠麻醉大鼠进行了血浆药代动力学研究,并评估了内酯、羧酸盐以及总药物的浓度-时间曲线。结果发现,给予CPT后内酯的血浆浓度和AUC值显著高于给予Na-CPT后。静脉注射后,内酯向组织中的明显快速且广泛摄取以及两种形式的快速清除导致血浆内酯与羧酸盐的比例发生偏差。从我们的结果来看,与给予CPT相比,Na-CPT较低的体内活性可能归因于与体外数据预测相比,体内羧酸盐向内酯的转化发生了改变。

相似文献

1
Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats.20(S)-喜树碱内酯和羧酸盐形式在麻醉大鼠体内的血浆药代动力学
Pharm Res. 1993 Oct;10(10):1451-7. doi: 10.1023/a:1018919224450.
2
Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.高效液相色谱法同时测定伊立替康(CPT-11)及其活性代谢物SN-38的内酯型和羧酸盐型:在大鼠血浆药代动力学研究中的应用
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jul 25;821(2):221-8. doi: 10.1016/j.jchromb.2005.05.010.
3
Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.给大鼠静脉注射7-乙基-10-羟基喜树碱(SN-38)和伊立替康(CPT-11)后7-乙基-10-羟基喜树碱(SN-38)的血浆药代动力学。
Biol Pharm Bull. 1997 Sep;20(9):992-6. doi: 10.1248/bpb.20.992.
4
Comparative brain tissue distribution of camptothecin and topotecan in the rat.喜树碱和拓扑替康在大鼠脑组织中的分布比较
Cancer Chemother Pharmacol. 1999;43(5):364-70. doi: 10.1007/s002800050908.
5
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.伊立替康及其代谢产物的临床药代动力学:一项群体分析。
J Clin Oncol. 2002 Aug 1;20(15):3293-301. doi: 10.1200/JCO.2002.11.073.
6
Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.伊立替康内酯和羧酸盐形式在啮齿动物胃肠道中的排泄及其药效学
Pharm Res. 2001 Jun;18(6):814-22. doi: 10.1023/a:1011040529881.
7
Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.伊立替康(CPT-11)羧酸盐和内酯形式及其代谢物SN-38在患者体内相互转化的动力学。
Cancer Res. 1994 Dec 15;54(24):6330-3.
8
Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.在基于细胞的筛选试验中评估伊立替康与顺铂的相互作用:非小细胞肺癌细胞系中的细胞毒性、药物蓄积及DNA加合物形成
Cancer Chemother Pharmacol. 2007 Jun;60(1):91-102. doi: 10.1007/s00280-006-0353-z. Epub 2006 Sep 29.
9
Effect of injection routes on pharmacokinetics and lactone/carboxylate equilibrium of 9-Nitrocamptothecin in rats.注射途径对大鼠9-硝基喜树碱药代动力学及内酯/羧酸盐平衡的影响。
Int J Pharm. 2007 Aug 1;340(1-2):29-33. doi: 10.1016/j.ijpharm.2007.03.008. Epub 2007 Mar 12.
10
Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma.反相高效液相色谱法同时定量血浆中喜树碱衍生物伊立替康(CPT-11)及其代谢产物SN-38的羧酸盐形式和内酯形式
J Chromatogr B Biomed Appl. 1994 Nov 4;661(1):133-41. doi: 10.1016/0378-4347(94)00340-8.

引用本文的文献

1
Camptothecin and its derivatives: Advancements, mechanisms and clinical potential in cancer therapy.喜树碱及其衍生物:在癌症治疗中的进展、机制和临床潜力。
Med Oncol. 2024 Oct 9;41(11):263. doi: 10.1007/s12032-024-02527-x.
2
Molecular Engineering of Peptide-Drug Conjugates for Therapeutics.用于治疗的肽-药物偶联物的分子工程
Pharmaceutics. 2022 Jan 17;14(1):212. doi: 10.3390/pharmaceutics14010212.
3
Hyaluronic acid conjugates for topical treatment of skin cancer lesions.透明质酸缀合物用于皮肤癌病变的局部治疗。

本文引用的文献

1
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.植物抗肿瘤剂。18. 喜树碱类似物的合成与生物活性
J Med Chem. 1980 May;23(5):554-60. doi: 10.1021/jm00179a016.
2
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.喜树碱(NSC - 100880)每周及每日治疗的I期临床试验:与临床前研究的相关性
Cancer Chemother Rep. 1972 Aug;56(4):515-21.
3
Treatment of malignant melanoma with camptothecin (NSC-100880).喜树碱(NSC-100880)治疗恶性黑色素瘤
Sci Adv. 2021 Jun 11;7(24). doi: 10.1126/sciadv.abe6627. Print 2021 Jun.
4
Toxicity of Carbon Nanomaterials and Their Potential Application as Drug Delivery Systems: In Vitro Studies in Caco-2 and MCF-7 Cell Lines.碳纳米材料的毒性及其作为药物递送系统的潜在应用:在Caco-2和MCF-7细胞系中的体外研究
Nanomaterials (Basel). 2020 Aug 18;10(8):1617. doi: 10.3390/nano10081617.
5
Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin.聚酰胺-胺树枝状聚合物作为喜树碱口服给药的吸收增强剂。
Int J Pharm. 2013 Nov 1;456(1):175-85. doi: 10.1016/j.ijpharm.2013.07.071. Epub 2013 Aug 8.
6
Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance.生物可降解纳米粒增强药物递送的纳米优势:清除减少的贡献。
Drug Metab Dispos. 2012 Jul;40(7):1380-8. doi: 10.1124/dmd.112.044925. Epub 2012 Apr 12.
7
Soluplus--solubilized citrated camptothecin--a potential drug delivery strategy in colon cancer.Soluplus——柠檬酸喜树碱增溶物——结肠癌潜在的药物传递策略。
AAPS PharmSciTech. 2012 Mar;13(1):59-66. doi: 10.1208/s12249-011-9720-0. Epub 2011 Nov 22.
8
Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine.机械化二氧化硅纳米颗粒:治疗诊断纳米医学的新前沿。
Acc Chem Res. 2011 Oct 18;44(10):903-13. doi: 10.1021/ar200018x. Epub 2011 Jun 15.
9
Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells.生物分子修饰的介孔硅纳米粒子的合成及其用于靶向输送疏水药物至癌细胞。
Small. 2011 Jul 4;7(13):1816-26. doi: 10.1002/smll.201002300. Epub 2011 May 19.
10
Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67.影响亲脂型喜树碱类似物 AR-67 体内内酯稳定性和全身清除率的因素。
Pharm Res. 2010 Jul;27(7):1416-25. doi: 10.1007/s11095-010-0137-3. Epub 2010 Apr 29.
Cancer Chemother Rep. 1972 Feb;56(1):103-5.
4
Renal clearance of camptothecin (NSC-100880): effect of urine volume.
Cancer Chemother Rep. 1973 Apr;57(2):175-84.
5
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.为期5天的治疗过程中血浆喜树碱(NSC - 100880)水平:与剂量及毒性的关系。
Cancer Chemother Rep. 1972 Oct;56(5):573-8.
6
Pharmacologic studies of camptothecin (NSC-100880): distribution, plasma protein binding, and biliary excretion.喜树碱(NSC - 100880)的药理学研究:分布、血浆蛋白结合及胆汁排泄
Cancer Chemother Rep. 1973 Apr;57(2):125-40.
7
DNA topoisomerases.DNA拓扑异构酶
Annu Rev Biochem. 1985;54:665-97. doi: 10.1146/annurev.bi.54.070185.003313.
8
DNA topoisomerase poisons as antitumor drugs.作为抗肿瘤药物的DNA拓扑异构酶毒物
Annu Rev Biochem. 1989;58:351-75. doi: 10.1146/annurev.bi.58.070189.002031.
9
On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex.关于喜树碱抑制拓扑异构酶I的机制:与酶-DNA复合物结合的证据。
Biochemistry. 1989 May 30;28(11):4629-38. doi: 10.1021/bi00437a018.
10
DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.DNA拓扑异构酶I介导的喜树碱类似物的DNA切割及细胞毒性
Cancer Res. 1989 Aug 15;49(16):4385-9.